Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23067775 | 1.00 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL29842503 | 1.00 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL23067773 | 1.00 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL23067788 | 0.94 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL29842524 | 0.94 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL23075269 | 0.94 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL23067786 | 0.94 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL23067751 | 0.93 | RIPK1 (0.89) | RIPK1 | |
| SCHEMBL23075391 | 0.93 | RIPK1 (0.89) | RIPK1 | |
| SCHEMBL23067749 | 0.93 | RIPK1 (0.89) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230057341-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20210070744-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2021046447-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070744-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-20230057341-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.